InvestWiser

Alligator Bioscience AB

ATORXNasdaq StockholmHealthcareMarket value 31 m SEK
0.01SEK +1.2%
last day · Price as of 18 November 2026

The answer first

Does Alligator Bioscience beat the market?

No, Alligator Bioscience has not beaten the market over the last year.

Alligator Bioscience−95.6%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 6% of Nordic stocks

    • Quality11
    • Value59
    • Trend1

    No. 173 of 195 in healthcare

Max for seven days

Follow Alligator Bioscience with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Alligator Bioscience

From today, at a price of 0.01 SEK. Write why you follow Alligator Bioscience, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Alligator Bioscience

Your first answer is free, no account needed.

Do you own Alligator Bioscience, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Alligator Bioscience and a few more. Free, no card.

Past year against the exchange and Super Stock
Alligator Bioscience−95.6%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Alligator Bioscience has fallen 95.6% over the past year, including dividends.
  • Overall, Alligator Bioscience ranks better than 6% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 100.0%. The price is 100.0% below its peak now.

What do analysts think of Alligator Bioscience?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

6

Quality, value and trend together. Better than 6% of Nordic stocks.

No. 173 of 195 in healthcare

Quality11
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 184 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity2.69
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−354.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value59
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 31 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.2
  • P/SPrice divided by sales19.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend1
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 196 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−58.8%
  • 6 months−93.9%
  • 9 months−93.1%
  • 12 months−95.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−25.0%
3 years, per year
−89.1%
5 years, per year
−78.7%
Year to date
−96.2%
Largest fall, 3 years
−100.0%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
166.0%
How much the price swings over a year
Beta, 1 year
1.29
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Alligator Bioscience

2 funds we follow own Alligator Bioscience. The share is how much of the fund the stock makes up.

  • Sweden2

From the funds' latest known holdings.

About Alligator Bioscience

Alligator Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.

See the full analysis of Alligator Bioscience.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market